药物基因组学研究遗传因素在药物安全性和有效性中的作用及临床意义，是个体化医学的核心关键。申请人近年来阐明了OATP等转运体遗传变异在药物药代和疗效中的作用，发现hERG等遗传变异是评价药物疗效和不良反应的新分子靶标，开展了天芪降糖等中药的药物基因组学和中西药物相互作用研究，建立了他克莫司等个体化用药剂量预测综合数学模型。获863计划课题和子课题、国家科技重大专项、国家自然科学基金青年和面上项目等课题16项，发表SCI论文67篇，26篇第一/通讯作者论文分别发表在Kidney Int、Trend Mol Med、Clin Pharmacokinet、Carcinogenesis等国际权威期刊，最高5篇平均IF值为6.56。主编和参编中英文教材专著15部。Pharmacogenomics（IF=3.45）杂志编委。获霍英东青年教师奖和赛诺菲青年生物制药奖。万人计划首批青年拔尖人才。

Pharmacogenomics studies the effect and clinical significance of genetic factors in the safety and efficacy of drugs, with the aim of personalized prevention and treatment of diseases. Within the last few years, the applicant has clarified the effect of genetic variations of OATP and other transporters in pharmacokinetics and pharmacodynamics, and discovered a few genetic variations including hERG as the new molecular biomarkers in the evaluation of drug efficacy and adverse reactions. In addition, he has also performed pharmacogenomic research of traditional Chinese medicine (TCM) such as Tianqi hypoglycemic capsule, studied the interaction between TCM and western medicine, and constructed a comprehensive mathematical model for personalized dosing prediction of tacrolimus and warfarin. The applicant has received 16 fundations including the 863 program, national science and technology major project, and national natural science foundation of youth and general projects. Among his 67 SCI papers, 26 were published as first or corresponding author in the international authoritative journals including Kidney Int, Trend Mol Med, Clin Pharmacokinet and Carcinogenesis, with a mean IF 6.56 of the top 5 papers. Editor for 15 Chinese and English textbooks and monographs, and editorial board member of Pharmacogenomics (IF=3.45). Moreover, he has been granted Henry Fok prize for young teachers, Senofi youth biopharmaceuticals award, and Plan for outstanding young scholars.